Inhibition of vascular endothelial growth factor‐A downregulates angiogenesis in psoriasis: A pilot study

Background Vascular Endothelial Growth Factor (VEGF)-A-mediated angiogenesis participates in the pathogenesis of psoriasis, thus inviting hypothesis that anti-VEGF-A therapy could be beneficial psoriasis. While anti-angiogenic agents are used oncology and ophthalmology, these therapeutic strategies remain unexplored for management Objective Our objective was to investigate ex vivo how VEGF-A blockade impacts blood vessels, epidermis immune cells organ-cultured plaque non-lesional skin from patients with Methods Skin biopsies psoriasis (n = 6; skin) healthy controls 6) were incubated monoclonal antibody (bevacizumab, Avastin®) or a human IgG1 isotype control 72-h serum-free organ culture. CD31/LYVE-1, Ki-67, mast cell tryptase expression assessed by quantitative immunohistomorphometry. levels plasma, PBMCs culture supernatants measured. Results Inhibition blocked all free vivo, reduced vessel area number endothelial plaques (*p < 0.05). The treatment effect correlated significantly (r 0.94; *p 0.05) plasma 0.943; 0.017). Conclusions These data first studies objectively potential inhibition as novel adjuvant strategy Taken together, our encourage further investigation clinical trial explore whether downregulating pathological has utility, especially severe those elevated and/or skin.